Apomorphine for Erectile Dysfunction — The Clinical Evidence

Apomorphine is among the most-studied centrally-acting treatments for erectile dysfunction. Unlike PDE5 inhibitors that act on penile blood vessels, it begins arousal in the brain — and multiple randomized trials have tested whether that translates into real-world erections.1

48–53%Attempts with erections firm enough for intercourse (vs. 35% placebo)2

~16–23Median minutes to erection with stimulation3

2 & 4 mgDoses with the best therapeutic index2

569Men in the pivotal 8-week randomized trial2

What the trials found

In an 8-week, multicenter, double-blind randomized trial of 569 men, every active sublingual apomorphine regimen beat placebo. Between 48% and 53% of attempts produced an erection firm enough for intercourse, versus 35% on placebo, and 45–51% of attempts ended in intercourse versus 33% — all statistically significant (P ≤ 0.001).2 A later meta-analysis summarized the effect as roughly a 20-percentage-point gain in successful intercourse over placebo.4

A 2006 comparative review concluded sublingual apomorphine offers the best balance of efficacy, safety and tolerability among its formulations — and stands as a viable first-line option alongside PDE5 inhibitors.1

Dosing & onset

Dose. Effective at just 2–4 mg sublingually; pooled data flagged 2 and 4 mg as the most acceptable therapeutic index.2
Onset. Rapid — a median of about 16–23 minutes to erection with sexual stimulation, since the sublingual route bypasses first-pass metabolism.3
Route. Sublingual only; swallowed apomorphine is largely inactivated before it can act.1

Who benefits most

Best suited for

✓ Mild-to-moderate ED with a central or psychogenic component
✓ Men wanting a fast-acting, low-dose, non-vascular mechanism
✓ Those who can't tolerate or don't respond to PDE5 inhibitors4

Less effective for

– Severe vascular ED, diabetes, or post-prostatectomy cases5
– Elderly men with multiple vascular risk factors1

Safety & side effects

The most common adverse events in trials were nausea, headache and dizziness — generally mild and dose-related, with nausea easing substantially over the first weeks of use.2 Because apomorphine can lower blood pressure and occasionally cause fainting, clinicians advise caution alongside antihypertensive medicines and monitoring in men with cardiovascular risk.1

Head-to-head, sildenafil generally produced stronger erectile responses; apomorphine's value is as a central-mechanism alternative, not a universal replacement.5

FDA status. Apomorphine is approved in the U.S. for Parkinson's disease, not ED. Branded sublingual ED tablets (Uprima/Ixense) were approved in Europe but are no longer marketed. Where used for ED it is compounded and prescribed off-label. This page is educational, not medical advice.5

Frequently asked questions

In the pivotal 569-man trial, 48–53% of attempts produced an erection firm enough for intercourse versus 35% on placebo, and a meta-analysis estimated roughly a 20-point gain in successful intercourse over placebo. It works best for mild-to-moderate ED.2 4

Taken sublingually at 2–4 mg, it produces an erection in a median of about 16–23 minutes with sexual stimulation. The 2 and 4 mg doses showed the most acceptable balance of effect and tolerability.2 3

Most commonly nausea, headache and dizziness — usually mild and dose-related, with nausea diminishing over the first weeks. It can lower blood pressure, so use caution with blood-pressure medication and under medical supervision.1 2

Not universally — in comparisons, sildenafil generally produced stronger erectile responses. Apomorphine's advantage is a different, central mechanism, making it an option for men with a psychogenic component or who can't use PDE5 inhibitors.5

Keep exploring

The Apomorphine–Dopamine Relationship →

The mechanism behind these results.

Top Ranked Apomorphine ED Treatments →

How the treatments compare.

Sources

Briganti A, et al. A comparative review of apomorphine formulations for erectile dysfunction: recommendations for use in the elderly. Drugs & Aging, 2006;23(4):309–319. pubmed.ncbi.nlm.nih.gov/16732690
Dula E, et al. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction (Apomorphine Study Group). pubmed.ncbi.nlm.nih.gov/10869641
BraveRx. Apomorphine for ED — dosing and onset. braverx.com/pages/apomorphine
BraveRx / meta-analysis summary. ~20-point gain in successful intercourse vs. placebo. braverx.com/pages/apomorphine
Ro Health Guide. Apomorphine for ED: efficacy, comparison to PDE5 inhibitors, and FDA status. ro.co/erectile-dysfunction/apomorphine-for-ed